Alkermes Plc (NASDAQ:ALKS)

44.37
Delayed Data
As of Apr 24
 -0.81 / -1.79%
Today’s Change
41.15
Today|||52-Week Range
71.22
-18.93%
Year-to-Date
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
Apr 18 / Zacks.com - Paid Partner Content
Company News For Apr 17, 2018
Apr 17 / Zacks.com - Paid Partner Content
Alkermes Rallies as FDA Accepts NDA for Depression Drug
Apr 17 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close45.18
Today’s open45.48
Day’s range44.08 - 45.92
Volume892,604
Average volume (3 months)1,175,431
Market cap$9.1B
Data as of 4:00pm ET, 04/24/2018

Growth & Valuation

Earnings growth (last year)+25.36%
Earnings growth (this year)-151.49%
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)+21.15%
P/E ratioNM
Price/Sales9.29
Price/Book7.49

Competitors

 Today’s
change
Today’s
% change
ALNYAlnylam Pharmaceutic...-1.13-1.18%
SGENSeattle Genetics Inc-1.02-2.05%
TSROTESARO Inc+1.04+2.00%
IONSIonis Pharmaceutical...-5.37-10.59%
Data as of 4:00pm ET, 04/24/2018

Financials

Next reporting dateApril 26, 2018
EPS forecast (this quarter)-$0.02
Annual revenue (last year)$903.4M
Annual profit (last year)-$157.9M
Net profit margin-17.48%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Richard F. Pops
President &
Chief Operating Officer
James Robinson
Corporate headquarters
Dublin, Dublin

Forecasts